DrugPatentWatch Database Preview
Secukinumab - Biologic Drug Details
Summary for secukinumab
| Tradenames: | 1 |
| Patents: | 13 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for secukinumab |
Recent Clinical Trials for secukinumab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Massachusetts General Hospital | Phase 2 |
| Novartis Healthcare A/S | Phase 4 |
| Professor Mikkel Østergaard | Phase 4 |
Pharmacology for secukinumab
| Mechanism of Action | Interleukin-17A Antagonists |
Patent Text Search: US Patents for secukinumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | COSENTYX | secukinumab | INJECTABLE;INJECTION | 125504 | 001 | 2016-01-15 | Start Trial | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | search | |
| Novartis Pharms Corp | COSENTYX | secukinumab | INJECTABLE;INJECTION | 125504 | 001 | 2016-01-15 | Start Trial | Pfizer Inc. (New York, NY) | 2039-02-26 | RX | search | |
| Novartis Pharms Corp | COSENTYX | secukinumab | INJECTABLE;INJECTION | 125504 | 001 | 2016-01-15 | Start Trial | Corning Incorporated (Corning, NY) | 2031-10-25 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for secukinumab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2017002064 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2015022656 | Start Trial |
| Slovenia | 2625199 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
